BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
An audio webcast of the presentations will be available live. You can access the webcasts at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-on-monday-january-8-at-1030-am-pt--130-pm-et-in-san-francisco-ca-302025143.html
SOURCE BioMarin Pharmaceutical Inc.